viewHeat Biologics

Heat Biologics: Meet the team behind a robust COVID-19 vaccine

Join Heat Biologics, AIM ImmunoTech, Avalon GloboCare, Oregenisis, and ImmunoPrecise Antibodies via the Proactive One2One Investor Forum, September 10, 1pm EDT.

Heat Biologics - Heat Biologics: Meet the team behind a robust COVID-19 vaccine

Heat Biologics Inc (NASDAQ:HTBX) is one of five biopharma companies presenting at Proactive’s online event on September 10 – all of them are playing a role to combat COVID-19.

The event kicks off at 1 pm EDT on Thursday, September 10.

This is an online variant of the popular conference format Proactive has run for more than a decade and enables communication between investors and management from some of the world's cutting-edge businesses.

SIGN-UP: Proactive One2One September 10

Heat Biologics, a clinical-stage biopharmaceutical, is developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine.

Thursday’s presentation follows some promising preclinical results from a study of a potential vaccine based on its already-developed gp96 platform.

A study found that Heat’s vaccine candidate “significantly increases the frequency of systemic and tissue-specific CD8+ T-cells by conferring cellular immunity that‘s essential against any viral infection, including SARS-CoV-2”, the virus that causes the COVID disease. 

It elicits a robust immune response directed against the Spike protein of SARS-CoV-2.

"We believe that these results are a powerful reinforcement that this platform represents a unique and relevant paradigm for novel vaccine development, capable of inducing cellular immune responses in epithelial tissues such as the lungs,” said Jeff Wolf chief executive.

The other companies on Thursday’s roster include AIM ImmunoTech Inc, Avalon GloboCare Corp (NASDAQ:AVCO), Oregenisis Inc (NASDAQ:ORGS), ImmunoPrecise Antibodies Ltd (CVE:IPA, OTCQB:IPATF).

Quick facts: Heat Biologics

Price: 1.14 USD

Market: NASDAQ
Market Cap: $182.22 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Heat Biologics named herein, including the promotion by the Company of Heat Biologics in any Content on the Site, the Company receives from...


Heat Biologics reveals its preclinical coronavirus vaccine results

Heat Biologics Inc (NASDAQ:HTBX) collaborator and University of Miami professor Dr Natasa Strbo tells Proactive the New York-based group has revealed positive preclinical coronavirus vaccine results. Dr Strbo says the data supports a differentiated gp96-based COVID-19 vaccine that induces...

on 08/26/2020

2 min read